KyrgyzstanTuberculosis profile
Population  2017 6 million
Estimates of TB burden*, 2017 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.4 (0.39–0.42) 6.7 (6.4–6.9)
Mortality (HIV+TB only) 0.073 (0.056–0.093) 1.2 (0.92–1.5)
Incidence  (includes HIV+TB) 8.7 (7.2–10) 144 (120–170)
Incidence (HIV+TB only) 0.31 (0.25–0.37) 5.1 (4.2–6.2)
Incidence (MDR/RR-TB)** 4.1 (3–5.4) 68 (50–89)
Estimated TB incidence by age and sex (thousands)*, 2017
  0-14 years > 14 years Total
Females 0.44 (0.43–0.46) 3.3 (3–3.7) 3.8 (3.3–4.2)
Males 0.49 (0.47–0.51) 4.4 (3.9–5) 4.9 (4.3–5.6)
Total 0.94 (0.88–0.99) 7.8 (6.5–9) 8.7 (7.2–10)
TB case notifications, 2017  
Total cases notified 7 695
Total new and relapse 6 687
          - % tested with rapid diagnostics at time of diagnosis 65%
          - % with known HIV status 89%
          - % pulmonary 76%
          - % bacteriologically confirmed among pulmonary 62%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2017 77% (65–92)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2017 0.06 (0.05–0.07)
TB/HIV care in new and relapse TB patients, 2017 Number (%)
Patients with known HIV-status who are HIV-positive 216 4%
          - on antiretroviral therapy 160 74%
Drug-resistant TB care, 2017 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  2 300
(2 200–2 400)
Estimated % of TB cases with MDR/RR-TB 26% (24–27) 61% (58–64)  
% notified tested for rifampicin resistance 46% 56% 3 757
MDR/RR-TB cases tested for resistance to second-line drugs   705
Laboratory-confirmed cases MDR/RR-TB: 1 372, XDR-TB: 134
Patients started on treatment **** MDR/RR-TB: 1 187, XDR-TB: 157
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2016 82% 6 072
Previously treated cases, excluding relapse, registered in 2016 67% 643
HIV-positive TB cases registered in 2016 57% 159
MDR/RR-TB cases started on second-line treatment in 2015 54% 1 162
XDR-TB cases started on second-line treatment in 2015 18% 51
TB preventive treatment, 2017  
% of HIV-positive people (newly enrolled in care) on preventive treatment 94%
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
33% (30–36)
TB financing, 2018  
National TB budget (US$ millions) 25
Funding source: 50% domestic, 47% international, 2% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2017 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2017
age_sex_graph
____
 
FemalesMalesIncidence

Treatment success rate (%)
tx success graph
   New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__
Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2018-12-13 Data: www.who.int/tb/data